AbbVie (WBO:ABBV) Float Percentage Of Total Shares Outstanding : 99.92% (As of May. 01, 2024)

View and export this data going back to 2018. Start your Free Trial

What is AbbVie Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AbbVie's float shares is 1,769.18 Mil. AbbVie's total shares outstanding is 1,770.65 Mil. AbbVie's float percentage of total shares outstanding is 99.92%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AbbVie's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AbbVie's Institutional Ownership is 48.95%.

AbbVie Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

AbbVie's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	1,769.18	/	1,770.65
	=	99.92%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie (WBO:ABBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (WBO:ABBV) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

ABBV:USA ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBV:Canada ABBV34:Brazil

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.